Abstract

Epithelial ovarian cancer is a disease with the highest mortality rate among gynecological tumors. After years of studies, despite targeted drugs and immunotherapies have been developing, their therapeutic effects are still not ideal. Statins, as lipid-lowering medicines, have many findings beyond expectation in the fight against cancer, and have shown promisingly positive results in clinical trials. Actually, statins cannot be used as a monotherapy to achieve complete remission due to its efficacy established, but for its great potential lying in effects about synergism and sensibilization with other drugs, and even the reduction of side effects of anti-cancer treatment. This review summarizes the evidence and potential of combining statins with first-line chemotherapy, bevacizumab, PARP inhibitors and immunotherapy drugs in the pharmacotherapy of ovarian cancer, and proposes hypothesises about new combination therapies based on the current mechanisms and theories, to provide a new perspective to further experimental research and clinical trials.